Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer
Background: Metastatic triple-negative breast cancer (mTNBC) is an aggressive subtype of breast cancer with poor survival. Currently, the literature lacks comprehensive real-world evidence on locally recurrent and mTNBC patients. To validate the optimal treatment for patients with mTNBC, real-world...
Main Authors: | Alan Celik, Tobias Berg, Maj-Britt Jensen, Erik Jakobsen, Hanne Melgaard Nielsen, Iben Kümler, Vesna Glavicic, Jeanette Dupont Jensen, Ann Knoop |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-10-01
|
Series: | Breast Cancer: Basic and Clinical Research |
Online Access: | https://doi.org/10.1177/11782234231203292 |
Similar Items
-
High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients
by: Kåre Nielsen, et al.
Published: (2023-11-01) -
Postcultural Communication? – Intercultural communication from a postcultural position
by: Iben Jensen
Published: (2015-03-01) -
Mobilen er med alle vegne – et praksisteoretisk bud på kulturbegrebet
by: Iben Jensen
Published: (2017-08-01) -
The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy
by: Changjing Cai, et al.
Published: (2022-09-01) -
Antimalarial pharmacokinetics and treatment regimens.
by: White, N
Published: (1992)